-
ALSO READ
Australia asks EU to review block of AstraZeneca Covid-19 vaccine
AstraZeneca says its coronavirus vaccine 76% effective in US phase-3 trial
Coronavirus vaccine: Germany reports more AstraZeneca clot cases
AstraZeneca US trial shows 79% efficacy against Covid-19 pandemic
AstraZeneca delivered 29.8 million Covid vaccine doses to European Union
-
The UK reported 25 new cases of rare blood clots possibly linked to AstraZeneca Plc’s Covid-19 vaccine, adding to the numbers that have caused some European countries to adopt precautionary measures. The fresh reports lift the total number of cases to 30 as of March 24, the Medicines and Healthcare Products Regulatory Agency said in a statement Thursday. The benefits of the shot continue to outweigh the risks, the regulator said. AstraZeneca’s vaccine, developed with the University of Oxford, is under mounting scrutiny and has faced dwindling support in Europe. Still, countries are counting on the shot to help them exit the pandemic, and millions of doses have been administered across the region. The UK agency said that the 30 incidents were out of 18.1 million doses of AstraZeneca vaccine given by March 24. Prior to that, the agency disclosed five cases on March 18, out of 11 million shots. With the new reports, the rate of incidents with the AstraZeneca shot in the UK is about 1 in 600,000. There were no reports of the same reactions to the vaccine from Pfizer Inc and BioNTech SE, which is also being used in Britain. “On the basis of this ongoing review, the benefits of the vaccines against Covid-19 continue to outweigh any risks and you should continue to get your vaccine when invited to do so,” the MHRA said.
The AstraZeneca and Pfizer vaccines have shown “very high levels of protection” against Covid-19, the agency said, adding that “all vaccines and medicines have some side effects.” The UK has one of the world’s fastest-moving vaccine programs, administering shots to more than half of all adults by late March. New daily Covid cases and deaths have fallen to the lowest levels since September, even as infections surge anew across much of the European Union, where immunisations have lagged. Earlier this week, the EU drugs regulator said a link between the AstraZeneca vaccine and a rare type of blood clot is possible, identifying at least 62 cases of the condition.
Dear Reader,
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.
Digital Editor
RECOMMENDED FOR YOU